Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aptose Biosciences, Inc.

< Previous 1 2 Next >
Aptose Announces Reverse Share Split
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Positive Decision by Nasdaq Hearings Panel
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Third Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Results from Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Adjournment of its Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Second Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Receipt of Deficiency Notice from Nasdaq
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Results from Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the First Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Fourth Quarter and Full Year 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Third Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.